Skip to main content

Table 3 Intravitreal Aflibercept Treatment and Outcomes Following Switch to Intravitreal Aflibercept

From: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration

  Patients
(n = 125)
Delay between last injection of ranibizumab and first IVT-AFL, days 61.2 (46.1)
Reasons for switch to IVT-AFL, n (%)
 Refractory 122 (97.6%)
 AE/SAE 3 (2.4%)
 Other 0 (0%)
Time between diagnosis of nAMD and first IVT-AFL, months 7.4 (3.3)
Duration of IVT-AFL treatment, months 11.3 (3.1)
Follow-up duration, months 12.7 (2.0)
Number of IVT-AFL injections 7.5 (2.6)
BCVA, ETDRS letters
 Baseline (switch to IVT-AFL) 66.2 (12.1)
 Month 12 67.7 (13.6)
 Change in BCVA score between baseline and 12 months 1.5 (10.3)
P value 0.105
CRT, μm
 Baseline (switch to IVT-AFL) 331.2 (103.3)
 Month 12 286.2 (84.7)
 Change in CRT between baseline and 12 months −45.0 (101.1)
P value <  0.001
Patients with SRF, n (%)
 Baseline 87 (70.7)
 Month 12 58 (48.3)
Patients with IRF, n (%)
 Baseline 44 (35.8)
 Month 12 27 (22.5)
  1. All values are reported as mean (standard deviation) unless otherwise indicated; per-protocol population
  2. P values are for the paired samples t test
  3. AE Adverse event, BCVA Best-corrected visual acuity, CRT Central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, IRF Intraretinal fluid;IVT-AFL Intravitreal aflibercept, nAMD Neovascular age-related macular degeneration, SAE Serious adverse event, SRF Subretinal fluid
\